leukemia/tyrosine

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 94 rezilta yo

Method and composition for detection of human chronic myelogenous leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION The present invention relates generally to methods and reagents used in the detection of cancer. More particularly, the present invention relates to a new diagnostic approach for the detection of chronic myelogenous leukemia. Leukemia is a malignant disease of the

Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Hyperproliferative disorders, such as cancer, are associated with the growth of abnormal, or neoplastic cells. In cancer, this uncontrolled cellular proliferation will often result in unregulated growth of malignant tissue and invasion of adjacent or local cells. Eventually, the malignant

Combination of clofazimine and imatinib for effective therapy of drug-resistant myeloid leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Indian Patent Application No. 201711030707, filed Aug. 30, 2017, the entirety of which is incorporated herein by reference. REFERENCE TO SEQUENCE LISTING Applicants assert that the paper copy of the Sequence Listing is

Reagents for the detection of protein phosphorylation in leukemia signaling pathways

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

RELATED APPLICATIONS This application claims the benefit of, and priority to, PCT serial number PCT/US06/034050, filed Aug. 31, 2006, presently pending, the disclosure of which is incorporated herein, in its entirety, by reference. FIELD OF THE INVENTION The invention relates generally to antibodies

Methods of treating leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to methods for treating leukemia, and more particularly, to the use of nucleoside analogues as an effective treatment for acute or chronic myelogenous leukemia. BACKGROUND OF THE INVENTION Leukemia is a malignant cancer of the bone marrow and

Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a

Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)im- idazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not Applicable. THE NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT Not Applicable INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC Not Applicable BACKGROUND OF THE INVENTION (1) Field of the Invention (2) Description

Human gene/protein involved in chronic myelogenous leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION Chronic myelogenous leukemia (CML) is a disease having clinical and pathological features distinct from those of other forms of leukemia. It is widely accepted that the cause of CML is a specific chromosomal translocation between human chromosome 9 and human chromosome

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The invention relates to a method of treating a warm-blooded animal, especially a human, having leukaemia comprising administering to the animal at least one compound inhibiting the c-Src protein tyrosine kinase activity, especially those compounds mentioned herein, in a quantity which is effective

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamid- e for the treatment of chronic myelogenous leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]- -benzamide, that inhibits the T315I mutation in

Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This invention relates to compounds. More specifically, the invention relates to compounds useful as kinase inhibitors, along with processes to prepare the compounds and uses of the compounds. Specifically, the invention relates to inhibitors of Bruton's tyrosine kinase (BTK). BACKGROUND Kinases are

Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

RELATED APPLICATIONS This application is a national phase filing under 35 U.S.C. 371 of International Application No. PCT/GB2015/051719, filed Jun. 11, 2015, which claims the benefit of and priority to United Kingdom Patent Application No. GB1410430.1, filed Jun. 11, 2014, the contents of which

Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This application is a national stage entry under 35 USC .sctn.371 of PCT/EP02/12076, filed Oct. 29, 2002, which claims benefit of Provisional Application No. 60/339,031 filed Oct. 30, 2001, and Provisional Application No. 60/338,185 filed Dec. 7, 2001, each of which is here incorporated by reference

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye